NASDAQ:ERNA Eterna Therapeutics (ERNA) Stock Price, News & Analysis $0.17 -0.05 (-22.93%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.18 +0.01 (+3.21%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eterna Therapeutics Stock (NASDAQ:ERNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eterna Therapeutics alerts:Sign Up Key Stats Today's Range$0.16▼$0.2550-Day Range$0.17▼$0.6452-Week Range$0.16▼$2.63Volume923,050 shsAverage Volume2.78 million shsMarket Capitalization$943,678.40P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Read More… Remove Ads Eterna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreERNA MarketRank™: Eterna Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Eterna Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eterna Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eterna Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEterna Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eterna Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.88% of the float of Eterna Therapeutics has been sold short.Short Interest Ratio / Days to CoverEterna Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eterna Therapeutics has recently increased by 6.03%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEterna Therapeutics does not currently pay a dividend.Dividend GrowthEterna Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.88% of the float of Eterna Therapeutics has been sold short.Short Interest Ratio / Days to CoverEterna Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eterna Therapeutics has recently increased by 6.03%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.18 News SentimentEterna Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eterna Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for ERNA on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Eterna Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eterna Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.49% of the stock of Eterna Therapeutics is held by insiders.Percentage Held by Institutions70.55% of the stock of Eterna Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eterna Therapeutics' insider trading history. Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ERNA Stock News HeadlinesEterna changes name to Ernexa TherapeuticsMarch 27, 2025 | markets.businessinsider.comEterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune DiseaseMarch 25, 2025 | markets.businessinsider.comA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....March 31, 2025 | Banyan Hill Publishing (Ad)Eterna hosts inaugural meeting of newly formed SABFebruary 26, 2025 | markets.businessinsider.comEterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy PipelineFebruary 26, 2025 | globenewswire.comEterna appoints Zeldis, Sather to scientific advisory boardJanuary 29, 2025 | markets.businessinsider.comEterna Therapeutics (NASDAQ:ERNA) Stock Quotes, Forecast and News SummaryJanuary 14, 2025 | benzinga.comEterna Announces Positive Preclinical Study Results On ERNA-101 In Ovarian Cancer; Stock Up 69%January 14, 2025 | markets.businessinsider.comSee More Headlines ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed this year? Eterna Therapeutics' stock was trading at $0.2940 at the beginning of the year. Since then, ERNA stock has decreased by 40.7% and is now trading at $0.1744. View the best growth stocks for 2025 here. How were Eterna Therapeutics' earnings last quarter? Eterna Therapeutics Inc. (NASDAQ:ERNA) issued its earnings results on Tuesday, November, 12th. The company reported ($4.92) EPS for the quarter. The business earned $0.49 million during the quarter. Who are Eterna Therapeutics' major shareholders? Eterna Therapeutics' top institutional shareholders include Geode Capital Management LLC (4.76%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include John D Halpern and Nicholas Jason Singer. View institutional ownership trends. How do I buy shares of Eterna Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eterna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eterna Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV). Company Calendar Last Earnings11/12/2024Today3/30/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERNA CIK748592 Webwww.brooklynitx.com Phone(212) 582-1199Fax760-438-3505Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,670,000.00 Net Margins-7,513.88% Pretax Margin-7,511.37% Return on EquityN/A Return on Assets-117.48% Debt Debt-to-Equity RatioN/A Current Ratio0.48 Quick Ratio0.48 Sales & Book Value Annual Sales$582,000.00 Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book0.43Miscellaneous Outstanding Shares5,411,000Free Float5,168,000Market Cap$943,678.40 OptionableNo Data Beta4.47 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ERNA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.